Upon joining the study, you will be required to provide written informed consent. This consent may be deferred, meaning it can be obtained after the initial emergency treatment if necessary.

You must have a clinical diagnosis of an acute ischemic stroke, which is a type of stroke caused by a blockage in a large blood vessel in the brain. This will be confirmed through imaging tests like a CT or MRI scan.

You will receive treatment with endovascular thrombectomy (EVT), a procedure that involves removing the blood clot causing the stroke. This is done through a small puncture in the groin area.

Before the EVT, a score of at least 10 on the National Institutes of Health Stroke Scale (NIHSS) is required. This scale measures the severity of your stroke symptoms.

Within 6 hours of the stroke onset, you will begin receiving the study medication, Acyl-ghreline, which contains the active substance lenomorelin.

The medication is administered as an intravenous bolus injection or infusion, which means it is given directly into your bloodstream through a vein.

Your neurological condition will be assessed using the NIHSS at 24 hours, 72 hours, and 7 days after the stroke onset. This helps to evaluate the effect of the medication on your stroke symptoms.

Additional assessments will include monitoring your blood glucose levels, blood pressure, and body temperature daily for up to 7 days or until discharge from the hospital.

At 90 days after the stroke, you will have follow-up evaluations to assess your recovery. This includes the modified Rankin Scale (mRS) to measure your level of disability, the Barthel Index to evaluate your ability to perform daily activities, and a telephone version of the Montreal Cognitive Assessment (t-MoCA) to check your cognitive function.

Your mortality status and any serious adverse events (SAEs) will also be recorded at this time.